EORTC Children's Leukemia Group

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
58921
Randomized phase III study comparing IDA versus MTZ in induction and intensification treatment of AML or MDS in children
58081
Translational research - observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukaemia (ALL).
58051
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia
58951
The value of 1) Dexamethasone vs prednisolone during induction 2) of prolonged versus conventional duration of L-Asparaginase therapy during consolidation and late intensification, in acute lymphoblastics leukemia and lymphoblastic non-Hodgkin lymphoma of childhood. A Randomised phase III study.
58953
Phase II Study of Fludarabine + Idarubicine + Aracytine in Refractory or Relapsed Acute Lymphocytic Leukemia in Children.
58941
Cyclosporine A after autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission. A phase I/II trial
58881
Randomized phase III study assessing the value of high-dose Ara-C during the interval therapy and of intravenous 6-MP during the maintenance in non B-cell acute lymphoblastic leukemia and non B-cell non-Hodgkin lymphoma of childhood
58871
Treatment of isolated CNS relapses occuring as first relapse in children with acute lymphoblastic leukemia by high dose Ara-C, intrathecal chemotherapy, and cranio-spinal radiotherapy. A phase II study.
58872
Pilot study of newly diagnosed acute myeloblastic leukemia (AML) in children
58831
Phase III trial comparing in a BFM protocol patients receiving cyclophosphamide or not during late induction for newly diagnosed acute lymphoblastic leukemia (ALL) in children with standard risk charasteristics.
58832
Phase III trial comparing as CNS prophylaxis radiotherapy vs no radiation therapy after high dose MTX for newly diagnosed acute lymphoblastic leukemia (ALL) in children with medium and high risk characteristics.

Back to Group-list